Best Stocks: A health care giant on our list is 'building a base' to go sharply higher

Johnson & Johnson (JNJ) is undergoing a significant strategic transformation, divesting its consumer products division (Kenvue) to focus on high-growth Innovative Medicines and MedTech sectors. This shift, alongside pipeline expansion and a more disciplined M&A approach, is driving strong financial performance, with JNJ raising its full-year 2025 sales guidance to $93.4 billion (5.4% YOY growth) and EPS guidance to $10.85 (8.7% YOY growth). After years of stock consolidation, these robust fundamentals and five consecutive quarters of post-Covid revenue growth are positioning JNJ for a potential stock breakout, with the market largely discounting the ongoing talcum powder litigation.

Analysis

Johnson & Johnson (JNJ) is undergoing a significant strategic overhaul, focusing on its high-growth Innovative Medicines and MedTech divisions after spinning off its consumer segment, Kenvue. This transition is demonstrating strong financial traction, with the company raising its full-year 2025 guidance to $93.4 billion in sales (+5.4% YoY) and $10.85 in EPS (+8.7% YoY), marking a potential sixth consecutive quarter of revenue growth. Key drivers include the MedTech division's 6.1% YoY revenue increase, led by a 22.3% surge in cardiovascular products, and an Innovative Medicine portfolio with 13 double-digit growing brands. This fundamental strength, supported by a disciplined M&A strategy and significant R&D investment ($6.7 billion YTD), coincides with a bullish technical setup. The stock has been consolidating in a wide base for five years and, with trailing twelve-month EPS at record highs, is now challenging the $180 resistance level. While a legal overhang from talcum powder lawsuits persists, the market appears largely unconcerned as JNJ pursues a new litigation strategy, suggesting the risk is mostly priced in.

Key Decisions for Investors

• Given the successful strategic pivot, strengthening fundamentals, and a supportive multi-year technical base, investors should consider JNJ a compelling opportunity with potential for significant capital appreciation upon a breakout above the $180 resistance level.
• The upcoming earnings report on October 14 is a primary near-term catalyst that could validate the bullish thesis and propel the stock out of its long-term consolidation range; this event warrants close attention.
• For risk management, the $150 price level serves as a critical support threshold, with a break below suggesting a potential change in the positive outlook, while the approximate 3% dividend yield offers income for investors holding the position.
• Although the market currently appears to discount the talcum powder litigation risk, investors should continue to monitor developments in JNJ's new individual case litigation strategy, as any unexpectedly adverse outcomes could reintroduce headline risk and volatility.